Pharmaceutical companies continue to lay out the ADC market, and an innovation war is inevitable

【Pharmaceutical Network Market Analysis】On September 7, Huadong Pharmaceutical announced that its wholly-owned subsidiary, Huadong Pharmaceutical Investment Holdings (Hong Kong) Co.
, Ltd.
(hereinafter referred to as "Huadong Investment"),has completed the delivery
of the public issuance of additional shares and the agreed transfer of shares of Heidelberg Pharma in Germany on September 6, 2022 (German time).

According to the data, Heidelberg Pharma is a global biopharmaceutical company focusing on the drug research and development of oncology ADC, with a proprietary ATAC® (Antibody Targeted Amanitin Conjugates) technology platform, and is the first company in the world to successfully develop Amanita muscarin and its derivatives for cancer treatment.
And successfully used the unique biological properties of the toxin to create a completely new treatment
.

It is understood that as early as February 27, Huadong Pharmaceutical signed the Equity Investment Agreement and the Product Exclusive License Agreement with Heidelberg Pharma
.

According to this announcement, after the completion of the delivery, Huadong Pharmaceutical's equity investment in Heidelberg Pharma Company has been successfully completed, and Huadong Investment holds 16,304,560 shares of Heidelberg Pharma Company, corresponding to holding 35.
00% of its equity, making it the second largest shareholder
.

Huadong Pharmaceutical said that by carrying out equity investment and product cooperation with Heidelberg Pharma, an emerging technology company in the field of ADC, and introducing a number of ADC innovative products, the company will further enrich the pipeline of innovative products in the field of oncology and achieve a differentiated in-depth layout
in the field of ADC.

In recent years, Huadong Pharmaceutical has been continuously increasing the depth of differentiation in the field of ADC, in addition to cooperation with Heidelberg Pharma, in recent years, it has also invested in the antibody research and development and production company Tsuen Xin Biological, ADC connector and coupling technology company Noling Biologics, incubated Hunda Biologics, which has a full product line of ADC drug toxin raw materials, and controlled the multi-antibody platform research and development company Doyle Biologics.
Equity investment and product cooperation with HeidelbergPharma, an emerging global technology company in the field of
ADC.

The industry expects that in the future, Huadong Pharmaceutical will form a unique ADC global R&D ecosystem, and gradually build a differentiated ADC independent R&D platform to strengthen and optimize the oncology product innovation chain and ADC ecological chain
.

It is worth noting that as one of the hot research directions in the field of tumor treatment, ADC has become a gathering place
for domestic and foreign pharmaceutical companies.

In recent years, a large number of multinational pharmaceutical companies such as Johnson & Johnson, GlaxoSmithKline, and Merck have begun to buy and develop ADC drugs.
Domestic pharmaceutical companies are also accelerating their share of the pie
.

The data shows that in terms of the progress of ADC development, as of the end of April this year, there have been a total of 67 ADC drug clinical trial information
in China.

Among them, 3 are applying for marketing, 9 are in phase III clinical trials, 8 are in phase II clinical trials, and 87 are in phase I clinical trials
.

In addition to Huadong Pharmaceutical, many enterprises have accumulated a lot of achievements
in the field of ADC.

For example, Hangzhou Duoxi Bio has a large number of ADC drugs under research, and there are already 18 ADC drugs in research, and the faster progress has entered phase II clinical trials
.

From the above point of view, the industry expects that a future ADC market war is inevitable
.

For domestic pharmaceutical companies, it will further test the wisdom of layout and the speed of
innovation.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.